Fig. 4: Efficacy endpoints of the gBRCAm cohort in modified intention-to-treat (mITT) patients. | Nature Communications

Fig. 4: Efficacy endpoints of the gBRCAm cohort in modified intention-to-treat (mITT) patients.

From: Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial

Fig. 4

A Pathological complete response (pCR) rate by treatment arm in gBRCAm patients. B pCR by cancer subtype in the entire trial population, excluding the dropped arm. The point estimation is the pCR response rate, and the error bar represents the 96% confidence interval of the proportion based on the Clopper–Pearson method. The statistical test was based on the two-sided chi-squared test. Source data is provided as a Source Data file.

Back to article page